Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Enrolls First Patient in Study Evaluating the Pharmacokinetics and Safety of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) in Osteoarthritis of the Shoulder and Hip
BURLINGTON, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has enrolled the first patient in a clinical trial to evaluate the pharmacokinetics and safety of ZILRETTA TM (triamcinolone acetonide extended-release injectable suspension) in
View HTML
Toggle Summary Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee
Acquisition complements existing portfolio with an innovative, locally administered therapeutic intended to provide persistent effective concentrations of IL-1Ra in the knee for at least a year New preclinical program holds potential to be a next-generation therapeutic that could provide
View HTML
Toggle Summary Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer
BURLINGTON, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Scott Kelley, M.D., has been named Chief Medical Officer. Dr. Kelley previously served as the company's Vice President of Medical Affairs, and in his new role, he assumes
View HTML
Toggle Summary Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) in Bilateral Osteoarthritis of the Knee
BURLINGTON, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the enrollment of the first patient in a clinical trial to evaluate the pharmacokinetics (PK) and safety of concurrent injections of ZILRETTA (triamcinolone acetonide extended-release
View HTML
Toggle Summary Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
BURLINGTON, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in a fireside chat at the BMO Capital
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BURLINGTON, Mass., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to three new employees for an aggregate of 20,500 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
View HTML
Toggle Summary Flexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
BURLINGTON, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in an analyst-led fireside chat at the
View HTML
Toggle Summary Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)
Recently approved, non-opioid therapy now available for the management of osteoarthritis knee pain Launch of ZILRETTA commences with full complement of field sales personnel deployed across the U.S. BURLINGTON, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc.
View HTML
Toggle Summary Flexion Therapeutics Named Top Place to Work for 2017 by The​ ​Boston​ ​Globe​
Annual survey recognizes and honors the best employers in Massachusetts BURLINGTON, Mass., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named one of the Top Places to Work in Massachusetts in the 10th annual employee-based survey
View HTML
Toggle Summary Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights
Zilretta TM (triamcinolone acetonide extended-release injectable suspension) received FDA approval for the management of osteoarthritis (OA) knee pain on October 6, 2017 Product was made commercially available on October 23, 2017, with full launch planned for late November Recent equity offering
View HTML